Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 9/20 | 0.62 |
| ▸ | CACNA2D1 | P54289 | 6/20 | 0.54 |
| ▸ | CACNB1 | Q02641 | 6/20 | 0.54 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.54 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.54 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 3/20 | 0.53 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3890903 | 0.90 | CACNA2D1 (0.64) | DRD3CACNA2D1CACNB1CACNA1BCACNA1C | |
| SCHEMBL3864509 | 0.88 | DRD3 (0.68) | DRD3CACNA2D1CACNB1CACNA1BCACNA1C | |
| SCHEMBL3871235 | 0.81 | CACNA2D1 (0.60) | DRD3CACNA2D1CACNB1CACNA1BCACNA1C | |
| SCHEMBL3888036 | 0.80 | DRD3 (0.60) | DRD3DRD2KDM4ETDP1ADRA1A | |
| SCHEMBL5027723 | 0.79 | KCNH2 (0.56) | DRD3CACNA1CDRD2ADRA1AADRA1B | |
| SCHEMBL5026257 | 0.78 | KCNA5 (0.59) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL3866660 | 0.78 | CACNA2D1 (0.53) | DRD3CACNA2D1CACNB1CACNA1BCACNA1C | |
| SCHEMBL5080776 | 0.76 | ALOX5 (0.53) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL5080780 | 0.75 | CACNA2D1 (0.49) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL5056246 | 0.74 | ALDH1A1 (0.69) | KDM4ETDP1MEN1TP53MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670775-A4 | PIPERAZINE SUBTITUTED COMPOUNDS USED AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD (CA) | 2009-04-22 | — | — | EP | claimed |
| US-7186726-B2 | Preferentially substituted calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-03-06 | — | — | US | claimed |
| JP-2007504174-A | — | — | 2007-03-01 | — | — | JP | claimed |
| EP-1670775-A1 | PIPERAZINE SUBTITUTED COMPOUNDS USED AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2006-06-21 | — | — | EP | claimed |
| WO-2005021523-A1 | PIPERAZINE SUBSTITUTED COMPOUNDS USED AS CALCIUM CHANNEL BLOCKERS | NEUROMED TECHNOLOGIES, INC. (CA) | 2005-03-10 | — | — | WO | claimed |
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-07-29 | — | — | US | claimed |
| US-20080300262-A1 | Combination Therapy for Relief of Pain | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-12-04 | — | — | US | disclosed |
| EP-1871372-A1 | COMBINATION THERAPY COMPRISING AN N-TYPE CALCIUM CHANNEL BLOCKER FOR THE ALLEVIATION OF PAIN | Neuromed Pharmaceuticals, Ltd. (CA) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006105670-A1 | COMBINATION THERAPY COMPRISING AN N-TYPE CALCIUM CHANNEL BLOCKER FOR THE ALLEVIATION OF PAIN | NEUROMED PHARMACEUTICALS LTD. (CA) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | CACNA1B, CACNA1C, CACNA1D | DRD3 759/4885CACNA2D1 36/4885CACNB1 13/4885 |
| US-20080300262-A1 | Combination Therapy for Relief of Pain | CACNA1B, TRPV1, ORAI1 | DRD3 1634/4885CACNA2D1 90/4885CACNB1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.